Conference abstract · 23 Jun 2023
Conference abstractPublished 20 Aug 2018
Biosimilars interchangeability: The draft guidance in the USA
International Expert in Biosimilars, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In the USA only interchangeable products can be substituted for the reference product by a pharmacist without the intervention of a health care provider. The interchangeability regulation is in the form of guidance: Interchangeable biologics must be biosimilar to the reference biologic.If administered more than once, data must show the safety and efficacy risks of switching. If not administered more than once, justify the omission of a switching study. The clinical data must demonstrate switching risk in all of the reference biologic’s licensed conditions of use.The data must support the “totality of the evidence” and “reduction of residual uncertainty”. Switching study design is de ned and described in the guidance. Guidance describes what is insuffiecient to demonstrate interchangeability. The use of post-marketing data from a biosimilar. The presentation and design attributes must be the same to enable substitution. The impact of biosimilar interchangeability in the USA will be more than positive. Where will an interchangeable biosimilar have the most impact? An interchangeability rating may result in the perception that the product is superior in quality to other biosimilars.How will payors react? Likely competitor response
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · Sep 2020
Biosimilars Interchangeability in the USA: The Final US-FDA Guidance to Industry
Conference abstract · 2019
The US-FDA interchangeability guidance for biosimilars
Other · 12 Jul 2016
Perspective on Adaptive Designs: 4 years European Medicines Agency reflection paper, 1 year draft US FDA guidance: where are we now?
Article · 2016
Assessment of Dependence Liability of New Molecular Entities under the Current FDA Draft Guidance Document: and#8220;Seeking Best Practicesand#8221
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- BylineArticles whose byline prints “Michel Mikhail”
